Print

Progenics Pharmaceuticals, Inc. (PGNX) Initiates Phase 2 Clinical Trial of PSMA ADC in Prostate Cancer Patients  
9/28/2012 10:21:15 AM

TARRYTOWN, N.Y., Sept. 28, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) has opened enrollment in a phase 2 study in prostate cancer patients of its PSMA ADC compound. PSMA ADC is a targeted anti-cancer therapeutic that uses a monoclonal antibody to deliver a cell-killing drug to malignant cells.
//-->